Document is current
Any future updates will be listed below
-
Authors
Uusküla-Reimand, Liis
Lee, Christian A.
Oh, Robin H.
Klein, Zoe P. https://orcid.org/0009-0000-0228-5503
Adler, Nina https://orcid.org/0000-0002-0297-2706
Akhtar Alvi, Sana https://orcid.org/0000-0003-4308-8244
Langille, Ellen
Pasini, Elisa
Cheng, Kevin C. L. https://orcid.org/0009-0008-8789-6378
Serafimova, Evgenija
Abd-Rabbo, Diala
Hou, Huayun https://orcid.org/0000-0003-3971-1427
Tsai, Ricky https://orcid.org/0000-0001-5916-6978
Bhat, Mamatha https://orcid.org/0000-0003-1960-8449
Schramek, Daniel https://orcid.org/0000-0001-9977-2104
Wilson, Michael D. https://orcid.org/0000-0002-4015-3066
Reimand, Jüri https://orcid.org/0000-0002-2299-2309
- License Information
-
More Information
Article History
Received: 18 December 2024
Accepted: 3 October 2025
First Online: 21 November 2025
Competing interests
: D.S. is a consultant for Tango Therapeutics and a founder of Viverita Therapeutics. M.B. reports grants from Natera, Eisai, AstraZeneca, Novo Nordisk, and Merck, grants and personal fees from Paladin, and nonfinancial support from CareDx outside the submitted work. The remaining authors declare no competing interests.
